

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

July 20, 2026

FHL/SEC/2026-27

The National Stock Exchange of India Ltd.

Scrip Symbol: FORTIS

BSE Limited

Scrip Code:532843

Sub: Press Release regarding appointment of Mr. Vijender Singh as Managing Director & Chief Executive Officer of Agilus Diagnostics Limited (a subsidiary of the Company).

Dear Madam/Sir,

Please find enclosed a copy of the press release being issued by the Company with respect to the appointment of Mr. Vijender Singh, as a Managing Director & Chief Executive Officer of Agilus Diagnostics Limited (a subsidiary of the Company), effective today.

The date and time of occurrence of event is July 20, 2026 at 11:00 AM.

This is for your information and record.

Thanking you,
Yours Sincerely,

For **Fortis Healthcare Limited**

Satyendra Chauhan
Company Secretary & Compliance Officer
M. No. – A14783
Encl.: as above

FORTIS HEALTHCARE LIMITED

Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062
Tel : 0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933

MEDIA RELEASE***Agilus Diagnostics Appoints Vijender Singh as Managing Director & Chief Executive Officer***

Gurugram, 20 July 2026: Agilus Diagnostics, one of India's leading diagnostic service providers, today announced the appointment of **Mr. Vijender Singh** as its **Managing Director & Chief Executive Officer (CEO)**. This follows the resignation of **Dr. Anand K**, who has decided to pursue opportunities outside the organisation after being associated with the company for nearly six years. The Board and management thank Dr. Anand K for his contributions to Agilus Diagnostics and wish him success in his future endeavours.

Mr. Vijender Singh brings with him over three decades of leadership experience across diagnostics, healthcare, consumer healthcare and FMCG sectors. He has a proven track record of building and scaling businesses, driving operational excellence, strengthening governance frameworks and creating high-performing organisations.

Prior to joining Agilus Diagnostics, Mr. Singh served as Chairman and Managing Director of Diagnum Healthcare, where he focused on strategic growth, governance and business development. He has previously held leadership positions as Group CEO of Metropolis Healthcare, CEO of Healthians and spent nearly a decade with Dr. Lal PathLabs, where he played a key role in building one of India's most successful diagnostics platforms. He has also worked with Jashvik Capital as an Operating Partner and held leadership roles with Ranbaxy Consumer Healthcare, Bausch & Lomb and Blow Plast.

Commenting on the appointment, **Dr. Ashutosh Raghuvanshi, Managing Director & Chief Executive Officer, Fortis Healthcare Limited and Chairman, Agilus Diagnostics**, said, *"We are delighted to welcome Vijender Singh as the Managing Director & Chief Executive Officer of Agilus Diagnostics. Vijender brings extensive experience in building and scaling diagnostic businesses, driving operational excellence and creating sustainable value across healthcare organisations. His deep understanding of the diagnostics industry, coupled with a strong track record of business transformation and customer-centric growth, makes him exceptionally well positioned to lead Agilus into its next phase of growth. As the diagnostics landscape continues to evolve, we believe his leadership will further strengthen our capabilities, accelerate innovation, enhance customer experience and reinforce Agilus' position as one of India's most trusted diagnostic brands."*

On his appointment, **Mr. Vijender Singh, Managing Director & Chief Executive Officer, Agilus Diagnostics**, said, *"I am excited to join Agilus Diagnostics at a time when the diagnostics industry is witnessing significant transformation and growth. Agilus has built a strong reputation for quality, scientific excellence and customer trust, supported by a vast network and talented team. I look forward to working closely with the leadership team and employees to further strengthen the organisation's market position, expand access to high-quality diagnostics, enhance operational excellence and create long-term value for patients, customers and all stakeholders."*



About Vijender Singh

Mr. Vijender Singh is a seasoned business leader with over 30 years of experience across diagnostics, healthcare, consumer healthcare and FMCG sectors. He has held senior leadership positions at some of India's leading diagnostics organisations, including Dr. Lal PathLabs, Metropolis Healthcare and Healthians.

At Dr. Lal PathLabs, he played a key role in building the company's retail-focused diagnostics model, strengthening operational excellence and contributing to its successful IPO journey. As Group CEO of Metropolis Healthcare, he led the integration and transformation of multiple acquired businesses, strengthened governance and operational efficiencies, and played a significant role in the company's successful public listing. Most recently, he served as Chairman and Managing Director of Diagnum Healthcare, focusing on strategic growth, governance and business development.

Widely recognised for his expertise in business transformation, operational excellence, customer experience and organisational leadership, Mr. Singh has consistently delivered profitable growth and scalable business models across the healthcare sector.

About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics, and day care specialty facilities. Currently, the company operates 36 healthcare facilities (including JVs and O&M facilities) across 12 states and union territories. The Company's network comprises over 6,000 operational beds (including O&M beds) and 400 diagnostics labs.

ABOUT IHH HEALTHCARE ("IHH")

IHH is a leading multinational healthcare provider shaping the future of care. Driven by our aspiration to Care. For Good., we unite medical excellence and innovation, pushing boundaries through our trusted brands such as Acibadem, Gleneagles, Fortis, Island, Mount Elizabeth, Pantai, Parkway and Prince Court. Across 10 countries, including Malaysia, Singapore, Türkiye, India and Greater China, our 70,000-strong team delivers world-class excellence every day, within and beyond our 140 healthcare facilities, including more than 80 hospitals. Our comprehensive services span the full healthcare continuum, from primary and ambulatory to quaternary care, complemented by diagnostics, imaging, rehabilitation, telehealth and home care. In partnership with our stakeholders, IHH is advancing value-based care, building a sustainable healthcare ecosystem and creating meaningful impact, as we work towards our vision to become the world's most trusted healthcare services network. www.ihhhealthcare.com

About Agilus Diagnostics

(A subsidiary of Fortis Healthcare Ltd.)

Instituted in 1995, Agilus Diagnostics Ltd., is one of India's largest diagnostics service providers in terms of number of laboratories in India as of and for the financial year ended March 31, 2023 (Source: CRISIL Report). Agilus Diagnostics has a network of 410+ labs, 3700+ customer touch points, and 12000+ direct clients/pick up points spread across 1000+ cities, 25 states and five union territories in India as of March 31, 2023. The company has recently undergone a brand transformation journey and has adopted a new name Agilus Diagnostics. Agilus is a portmanteau of 'Agile' and 'Us' and is inspired from the Latin term 'agilis' which means 'agility'. Agilus offers more than 3,000 tests and test combinations, ranging from routine tests to esoteric and genetic tests. The company has the largest number of NABL accredited labs in the country as of March 31, 2023 (Source: CRISIL Report) with 43 NABL accredited labs, 3 NABL M(EL)T certified labs and 2 CAP accredited labs. Its international network consists of centers across the SAARC region, Sub-Saharan Africa, South-East Asia and the Middle East. Agilus is committed to research and development and focused on genomics and 'next-generation diagnostics' and delivering a customer-centric experience through integrated and seamless technology platforms and data-driven actionable insights.



For more information, please contact:

Fortis Healthcare Ltd.	Adfactors PR
Head - Corporate Communications Ajeay Maharaj: +919871798573 ajeay.maharaj@fortishealthcare.com	Saadia Farrukh: +91 7838076088 saadia.farrukh@adfactorspr.com